STORY

NEWS

AIBIOTICS ‘All-in-One PCR for On-site Diagnosis’ Wins 2022 Digital Innovation ‘Grand Prize’

AIBIOTICS ‘All-in-One PCR for On-site Diagnosis’ Wins 2022 Digital Innovation ‘Grand Prize’

AiBiotics (CEO Ma Sang-bae, Ma Sang-hyuk), a startup specializing in biohealthcare, announced on the 11th that it has won the 17th Digital Innovation BT Award in 2022 organized by The Korea Times.
AI Biotics (CEOs Ma Sang-bae and Ma Sang-hyuk) is developing an ‘all-in-one RT-PCR device for point-of-care (POCT)’ that can test infectious diseases such as COVID-19 in real time. This dramatically improves analysis time and convenience by implementing the existing test system divided into nucleic acid extraction, amplification, and detection all in one device. Compared to some commercialized foreign-made rapid PCR test equipment for on-site diagnosis, it has excellent advantages for multiplex diagnosis, which can diagnose various diseases at once. Not many people realize that most of the reagents and equipment used in corona PCR tests are foreign-made. “In order for K-Bio to have international competitiveness, it is very important to develop and distribute domestic equipment,” said Ma Sang-bae, a former semiconductor engineer who is in charge of development. “The goal is to create a diagnostic device that is not just a diagnostic device but a tool that connects doctors and patients, and a diagnostic device that is close to life.”
Co-CEO Ma Sang-hyuk, a practicing physician, said, “We will create a diagnostic device that is essential for hospitals by directly participating in development.”

AiB

Principled, forward-thinking, values-driven companies
5-404, 21, Bongambuk 7-gil, Masanhoewon-gu, Changwon-si, Gyeongsangnam-do, Republic of Korea
Tel. 031-695-6058
Principled, forward-thinking, values-driven companies

AiB

원칙에 충실하고, 미래지향적이며 가치 중심적인 기업
경상남도 창원시 마산회원구 봉암북7길 21, 5동 404호
Tel. 031-695-6058
원칙에 충실하고,
미래지향적이며 가치 중심적인 기업